CICC Capital Research
Investment Thesis
CICC Capital is the private equity investment platform wholly owned by China International Capital Corporation (CICC), one of China's leading investment banks. Founded in 2017 and headquartered in Beijing, CICC Capital's stated ambition is to be a leading "sci-tech" investment institution, aiming to help build China into a global science and technology powerhouse. The firm invests in companies with long-term growth potential, durable core competitiveness, and strong management teams, deploying capital both domestically in China and, increasingly, cross-border as Chinese "new economy" companies expand internationally.
Sector Focus
CICC Capital has built a diversified portfolio spanning frontier technologies (semiconductors, AI), high-end manufacturing, healthcare, consumer goods and services, new energy, new materials, environmental conservation, and next-generation services. Its most visible bets sit in hard tech and deep tech: semiconductor equipment and memory manufacturing, medical imaging hardware, AI software, and, most recently, controlled nuclear fusion. Healthcare (particularly pharmaceuticals and medical devices) is a recurring theme alongside advanced manufacturing and industrial technology.
Stage Focus
CICC Capital operates as a private equity investor rather than an early-stage venture fund. Its portfolio skews toward growth-stage and pre-IPO companies, several of which are already publicly listed (SenseTime, Advanced Micro-Fabrication Equipment/AMEC, United Imaging). Where it participates in earlier rounds, it tends to be substantial Series A rounds for deep-tech, capital-intensive businesses (e.g., a ~$143M Series A for a nuclear fusion startup) rather than typical seed-stage checks.
Check Size
Individual check sizes are not publicly disclosed with precision, but CICC Capital participates in and co-leads large rounds — its share of the ~$143M (CNY 1B) Startorus Fusion Series A illustrates a capacity for sizeable, capital-intensive deep-tech checks alongside other institutional and government-backed co-investors.
Lead Tendency
CICC Capital both leads and co-leads. It jointly led Startorus Fusion's Series A alongside three Shanghai state-owned investment firms, and it has taken a general-partner role (via its BlueFive Capital partnership) in fund-of-funds vehicles it helps originate, indicating an active, structuring role rather than a passive follower position.
Recent Activity
CICC Capital has been active through early 2026. In January 2026 it co-led Startorus Fusion's ~$143M Series A for commercial nuclear fusion development. Around the same period, BlueFive Capital was appointed the founding general partner of the CICC–HBIS Development Fund, a RMB32B ($4.58B) fund-of-funds formed with Chinese steelmaker HBIS Group targeting advanced materials, new energy, and next-generation information technology. In August 2025, CICC Capital and BlueFive Capital announced a partnership to launch a private equity fund helping Chinese "new economy" companies (technology, digital transformation, green energy, advanced manufacturing, and consumer sectors) expand into GCC markets, using the Gulf as both a market-entry point and a springboard to broader international expansion.
Portfolio Highlights
Notable portfolio companies include SenseTime (AI/computer vision, publicly listed), United Imaging Healthcare (medical imaging equipment, publicly listed), Changxin Memory Technologies/CXMT (DRAM memory manufacturing), Advanced Micro-Fabrication Equipment/AMEC (semiconductor etch and deposition equipment, publicly listed), Startorus Fusion (controlled nuclear fusion), Youlin Pharmaceutical (healthcare), SJ Semi (semiconductors), and Baiyang Intelligence.
Team
- Mengyang Yang — Executive Director and Head of Hong Kong PE Business
- Qing Gao — Managing Director
- Huan Yang — Senior Vice President
- Chenlong Li — Vice President
Decision Process
As a subsidiary of a major state-linked investment bank, CICC Capital operates with institutional governance rather than a solo-GP or small-partnership structure; investment decisions run through formal committee and institutional approval processes typical of bank-affiliated PE platforms.
Founder Preferences
CICC Capital gravitates toward technically differentiated, capital-intensive businesses in hard tech and healthcare — companies with defensible IP, strong engineering/scientific teams, and a credible path to scale (often pre-IPO or already public), rather than early-stage, unproven consumer or software startups.
Geographic Focus
Primarily mainland China, with Hong Kong PE operations and an expanding cross-border mandate into GCC/Middle East markets via its BlueFive Capital partnership, positioning the Gulf as a gateway for Chinese companies' international expansion.
AUM and Fund Status
As of December 31, 2024, CICC Capital managed approximately RMB 450 billion (~$62 billion) in assets across private equity funds and funds-of-funds. The firm is actively deploying and originating new vehicles, including the RMB32B CICC–HBIS fund-of-funds and the CICC–BlueFive GCC-focused fund.